Acrivon Therapeutics (ACRV) Liabilities and Shareholders Equity (2021 - 2026)

Acrivon Therapeutics (ACRV) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $107.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 38.85% year-over-year to $107.8 million; the TTM figure through Mar 2026 stood at $541.4 million (down 33.83% YoY), while the FY2025 annual figure was $129.7 million, down 34.02% from the prior year.
• Liabilities and Shareholders Equity retreated to $107.8 million in Q1 2026 per ACRV's latest filing, from $129.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $230.6 million in Q2 2024 and bottomed at $87.7 million in Q3 2022.
• Historically, Liabilities and Shareholders Equity has averaged $157.9 million across 5 years, with a median of $158.6 million in 2025.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity surged 72.26% — and 2026, when it tumbled 38.85%.
• Acrivon Therapeutics' Liabilities and Shareholders Equity stood at $181.2 million in 2022, then declined by 23.71% to $138.3 million in 2023, then jumped by 42.18% to $196.6 million in 2024, then plunged by 34.02% to $129.7 million in 2025, then slipped by 16.87% to $107.8 million in 2026.
• Business Quant data shows ACRV's Liabilities and Shareholders Equity at $107.8 million in Q1 2026, $129.7 million in Q4 2025, and $145.3 million in Q3 2025.